ArticleCureus2025
Successful Use of OviTex® Bridging Repair in a Super Morbidly Obese Patient With Septic Shock, Perforated Diverticulitis, and Necrotizing Fasciitis of the Abdominal Wall.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Managing abdominal wall defects in contaminated surgical fields is particularly challenging in super morbidly obese patients with severe infection. We report the case of a 49-year-old man (BMI 54, 195 kg) who presented in septic shock with necrotizing fasciitis of the abdominal wall secondary to perforated diverticulitis and colocutaneous fistula. Initial management included exploratory laparotomy, extensive debridement of a 25 × 25 cm abdominal wall abscess, anterior resection left in discontinuity, and temporary abdominal closure with an AbThera™ wound vacuum (Solventum, Saint Paul, MN, USA). Once stabilized, the patient underwent definitive repair with the placement of a 25 × 25 cm inlay OviTex® 2S permanent reinforced tissue matrix (manufactured by TELA Bio, Inc., Malvern, PA, USA), the creation of an end colostomy, and wound vacuum placement. Postoperatively, he recovered steadily, was weaned from ventilatory support, tolerated oral intake, and demonstrated functional colostomy output. He was discharged home with a wound vacuum and returned to full function within two months. At six months, he had stable abdominal wall integrity after skin grafting, with plans for staged colostomy reversal and abdominal wall reconstruction after weight loss. This case highlights the successful use of OviTex® in providing both mechanical strength and biologic integration in a high-risk patient where permanent synthetic mesh was contraindicated and biologic mesh alone would have been inadequate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.